Propanc Biopharma Secures $100 Million in Funding from Hexstone Capital

Propanc Biopharma secures $100 million in funding to advance oncology therapy and explore digital assets.

Fridah Kangai
November 11, 2025
1:00 pm

Fridah Kangai

Fridah Kangai is a dedicated crypto journalist with a sharp eye for market trends, blockchain innovation, and digital asset movements. She specializes in breaking down complex topics into clear, engaging stories for both seasoned investors and curious newcomers. With a passion for decentralization and a pulse on the ever-evolving crypto space, Fridah delivers timely, accurate, and insightful coverage. Her work bridges the gap between technology and everyday understanding in the world of cryptocurrency.

Propanc secures $100 million investment to enhance oncology therapy.
Biotech sector embraces digital assets for funding amid market uncertainty.
Propanc’s stock drops despite securing major funding from Hexstone.

Propanc Biopharma, an Australian biotech company, has announced a $100 million financing deal with Hexstone Capital. The deal, structured through a private placement of convertible preferred stock, includes an initial investment of $1 million. Propanc can secure a follow-on of up to $ 99 million in the coming year.

The capital will be utilized to increase the number of digital assets and Propanc Oncology Therapy PRP. PRP will start first-in-human trials in 2026. CEO James Nathanielsz described this financing as a transformative phase for the company. He emphasized the need to consolidate the company’s balance sheet and further develop the proenzyme-based research program.

Also Read: Trump Media’s $54.8M Loss Sparks Alarming Drop as Crypto Gamble Raises Stakes

Biotech Firms Turn to Digital Assets

The trend here is showing a rising trend by biotech companies in their quest to raise funds via digital assets. With capital markets tightening, several small biotech companies are turning to cryptocurrency and digital assets to attract interest. Propanc is not the only one who took an interest in this new avenue.

Sonnet BioTherapeutics, Sharps Technology, and other companies have shifted to digital assets to secure funds and gain market relevance.

Challenges Ahead for Propanc’s Stock Performance

Although there was excitement over the announcement of funding, the stock price of Propanc dropped by 4 percent after the news. There has been a further decline in the share price, with PPCB shares falling 43 percent over the last month. This company’s business is not financially stable, despite having a large financing deal.